BIOVENTUS INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
BIOVENTUS INC. (BVS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $8.60 per share for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- BIOVENTUS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-28 was $8.60, a 10.60% decline year-over-year.
- BIOVENTUS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-29 was $9.62, a 85.71% increase year-over-year.
- BIOVENTUS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-30 was $5.18, a 98.47% increase year-over-year.
- BIOVENTUS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-04-01 was $2.61, a 79.38% decline year-over-year.
- BIOVENTUS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $9.29, a 71.40% increase from fiscal 2024.
- BIOVENTUS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $5.42, a 323.44% increase from fiscal 2023.
- BIOVENTUS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.28, a 89.50% decline from fiscal 2022.
- BIOVENTUS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $12.19, a 9.62% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-27 | $8.60 10-Q · filed 2026-08-05 | |||
| 2026-03-28 | $8.60 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $9.29 10-K · filed 2026-03-05 | |||
| 2025-09-27 | $9.36 10-Q · filed 2025-11-04 | |||
| 2025-06-28 | $9.36 10-Q · filed 2025-08-06 | |||
| 2025-03-29 | $9.62 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $5.42 10-K · filed 2026-03-05 | |||
| 2024-09-28 | $5.18 10-Q · filed 2024-11-05 | |||
| 2024-06-29 | $5.18 10-Q · filed 2024-08-06 | |||
| 2024-03-30 | $5.18 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $1.28 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $1.21 10-Q · filed 2023-11-07 | |||
| 2023-07-01 | $1.19 10-Q · filed 2023-08-08 | |||
| 2023-04-01 | $2.61 10-Q · filed 2023-05-16 | |||
| 2022-12-31 | $12.19 10-K · filed 2024-03-12 | |||
| 2022-10-01 | $12.28 10-Q · filed 2022-11-21 | |||
| 2022-07-02 | $12.62 10-Q · filed 2022-08-12 | |||
| 2022-04-02 | $12.66 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $11.12 10-K · filed 2023-03-31 | |||
| 2021-10-02 | $14.90 10-Q · filed 2021-11-10 | |||
| 2021-07-03 | $14.90 10-Q · filed 2021-11-10 | |||
| 2021-04-03 | $13.03 10-Q · filed 2021-11-10 |